197 related articles for article (PubMed ID: 17547682)
1. The Leu544Ile polymorphism of the growth hormone receptor gene affects the serum cholesterol levels during GH treatment in children with GH deficiency.
Ihara K; Inuo M; Kuromaru R; Miyako K; Kohno H; Kinukawa N; Hara T
Clin Endocrinol (Oxf); 2007 Aug; 67(2):212-7. PubMed ID: 17547682
[TBL] [Abstract][Full Text] [Related]
2. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
Binder G; Trebar B; Baur F; Schweizer R; Ranke MB
Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
[TBL] [Abstract][Full Text] [Related]
3. Comparison between weight-based and IGF-I-based growth hormone (GH) dosing in the treatment of children with GH deficiency and influence of exon 3 deleted GH receptor variant.
Marchisotti FG; Jorge AA; Montenegro LR; Berger K; de Carvalho LR; Mendonca BB; Arnhold IJ
Growth Horm IGF Res; 2009 Apr; 19(2):179-86. PubMed ID: 19036620
[TBL] [Abstract][Full Text] [Related]
4. Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor.
Meyer S; Ipek M; Keth A; Minnemann T; von Mach MA; Weise A; Ittner JR; Nawroth PP; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Kann PH; ;
Growth Horm IGF Res; 2007 Aug; 17(4):307-14. PubMed ID: 17462934
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the -629C>A CETP promoter polymorphism in GH-receiving hypopituitary patients.
Dullaart RP; Schols JL; van der Steege G; Zelissen PM; Sluiter WJ; van Beek AP
Clin Endocrinol (Oxf); 2008 Sep; 69(3):359-66. PubMed ID: 18221399
[TBL] [Abstract][Full Text] [Related]
6. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
[TBL] [Abstract][Full Text] [Related]
7. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
8. GH receptor d3 polymorphism in Dutch patients with MPHD and IGHD born small or appropriate for gestational age.
de Graaff LC; Meyer S; Els C; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Jun; 68(6):930-4. PubMed ID: 18031312
[TBL] [Abstract][Full Text] [Related]
9. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism in genes of growth hormone receptor (GHR) and insulin-like growth factor-1 (IGF1) and its association with both the IGF1 expression in liver and its level in blood in Polish Holstein-Friesian cattle.
Maj A; Snochowski M; Siadkowska E; Rowinska B; Lisowski P; Robakowska-Hyzorek D; Oprzadek J; Grochowska R; Kochman K; Zwierzchowski L
Neuro Endocrinol Lett; 2008 Dec; 29(6):981-9. PubMed ID: 19112400
[TBL] [Abstract][Full Text] [Related]
11. Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children.
Pilotta A; Mella P; Filisetti M; Felappi B; Prandi E; Parrinello G; Notarangelo LD; Buzi F
J Clin Endocrinol Metab; 2006 Mar; 91(3):1178-80. PubMed ID: 16394090
[TBL] [Abstract][Full Text] [Related]
12. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
Wan L; Chen WC; Tsai Y; Kao YT; Hsieh YY; Lee CC; Tsai CH; Chen CP; Tsai FJ
Pediatr Res; 2007 Dec; 62(6):735-40. PubMed ID: 17957148
[TBL] [Abstract][Full Text] [Related]
13. Associations of the growth hormone receptor (GHR) gene polymorphisms with adiposity and IGF-I activity in adolescents.
Mong JL; Ng MC; Guldan GS; Tam CH; Lee HM; Ma RC; So WY; Wong GW; Kong AP; Chan JC; Waye MM
Clin Endocrinol (Oxf); 2010 Sep; 73(3):313-22. PubMed ID: 20105189
[TBL] [Abstract][Full Text] [Related]
14. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
Audí L; Carrascosa A; Esteban C; Fernández-Cancio M; Andaluz P; Yeste D; Espadero R; Granada ML; Wollmann H; Fryklund L;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
[TBL] [Abstract][Full Text] [Related]
16. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement.
Brooke AM; Kalingag LA; Miraki-Moud F; Camacho-Hübner C; Maher KT; Walker DM; Hinson JP; Monson JP
Clin Endocrinol (Oxf); 2006 Nov; 65(5):673-80. PubMed ID: 17054472
[TBL] [Abstract][Full Text] [Related]
17. A novel mutation of exon 7 in growth hormone receptor mRNA in a patient with growth hormone insensitivity syndrome and neurofibromatosis type I.
Kang JH; Kim OS; Kim JH; Lee SK; Park YJ; Baik HW
Int J Mol Med; 2012 Sep; 30(3):713-7. PubMed ID: 22751808
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone (GH1) gene variation and the growth hormone receptor (GHR) exon 3 deletion polymorphism in a West-African population.
Millar DS; Lewis MD; Horan M; Newsway V; Rees DA; Easter TE; Pepe G; Rickards O; Norin M; Scanlon MF; Krawczak M; Cooper DN
Mol Cell Endocrinol; 2008 Dec; 296(1-2):18-25. PubMed ID: 18950677
[TBL] [Abstract][Full Text] [Related]
20. Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency.
Räz B; Janner M; Petkovic V; Lochmatter D; Eblé A; Dattani MT; Hindmarsh PC; Flück CE; Mullis PE
J Clin Endocrinol Metab; 2008 Mar; 93(3):974-80. PubMed ID: 18029459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
